for the REVEAL Investigators D ESPITE ADVANCES IN THE management of ST-segment elevation myocardial infarction (STEMI), it remains a significant cause of morbidity, mortality, and disability, 1,2 particularly among older persons. 3 Patients who survive STEMI are at risk for developing infarct expansion (the process of myocardial thinning and in-farct zone dilation that begins soon after coronary occlusion) 4 and left ventricular (LV) remodeling (the topographical and functional changes in the in-For editorial comment see p 1908.
farct zone and the noninfarcted myocardium). 5 Both are strongly associated with heart failure and death. 6 Risk factors for infarct expansion and LV remodeling include infarct size, extent of apoptosis, anterior location of the infarction, 7 severe microvascular obstruction, 8 and older age. 9 Given the global burden of ischemic heart disease and heart failure, therapies that limit infarct size and attenuate or reverse LV remodeling are needed.
Erythropoietin is a 165-amino acid glycoprotein hormone whose production and secretion are regulated by tissue oxygen levels. Beyond its effects on red blood cell production, erythropoietin exhibits pleiotropic effects in cells and tissues, including stimulation of angiogenesis and protection against apoptosis. 10 Furthermore, erythropoietin receptors have been identified on endothelial cells and cardiomyocytes. 11 Preclinical studies have shown that erythropoietin plays a cardioprotective role in various experimental models of myocardial ischemia and ischemia reperfusion. [12] [13] [14] [15] [16] [17] In these investigations, erythropoietin was associated with significant reductions in infarct size and improvements in LV function that were partly attributed to its antiapoptotic and angiogenic properties.
To determine whether erythropoietin has similar cardioprotective effects in a clinical setting, we performed the Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) trial, which evaluated the safety and effect on infarct size of a single intravenous bolus of recombinant human erythropoietin (epoetin alfa) in patients with STEMI who have undergone successful primary or rescue percutaneous coronary intervention (PCI).
METHODS
The REVEAL trial was a multicenter, phase 2, randomized, double-blind, placebo-controlled clinical trial that evaluated the safety and efficacy of a single intravenous bolus of epoetin alfa in patients with STEMI. The design and rationale of the REVEAL trial have been published. 18 Briefly, the study consisted of a dose-escalation phase and an efficacy phase (FIGURE 1) . During the doseescalation phase, 3 doses of epoetin alfa (15 000 U, 30 000 U, and 60 000 U) were sequentially evaluated. These doses were chosen with guidance from the US Food and Drug Administration to balance safety concerns with the relatively high doses of erythropoietin used in preclinical studies. Patients were randomly allocated in a 2 to 1 ratio to each dose of epoetin alfa or placebo, respectively. Dose escalation was guided by an independent data and safety monitoring board, which reviewed clinical and safety data at 2 time points for each dose cohort. 18 Based on the study design, the highest planned dose of epoetin alfa that was deemed acceptable by the data and safety monitoring board was used in the efficacy phase, in which participants were randomly allocated in a 1 to 1 ratio to epoetin alfa or placebo. The REVEAL study was reviewed and approved by the MedStar Research Institute's institutional review board and by the respective institutional review boards of the participating sites. Written informed consent was obtained from all participants or their legally authorized representatives.
In accordance with guidelines from the National Institutes of Health, selfreported information on race and ethnicity was collected from all study participants. Categories were defined by the study investigators and consisted of Hispanic/Latino or non-Hispanic/Latino for ethnicity and American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, other (which were later condensed into 1 category), white, or black/ African American for race.
Eligibility Criteria, Randomization, and Study Medication
Study eligibility criteria are listed in eTable 1 at http://www.jama.com. Briefly, patients were eligible if they had acute STEMI with a Thrombolysis in Myocardial Infarction (TIMI) flow grade of 0 to 1 in a major epicardial ar-tery or large branch vessel during index angiography and underwent successful primary or rescue PCI within 8 hours of onset of ischemic symptoms. To minimize confounding of the measurement of infarct size, patients with a history of LV dysfunction (LV ejection fraction [LVEF] Յ50%), MI, coronary artery bypass grafting, or revascularization in the territory of the culprit artery were excluded.
Eligible patients were randomly assigned to epoetin alfa or matching placebo according to the allocation ratio for each dosing cohort. Randomization was performed with a fixed-block randomization scheme using a Webbased application (WebEZ, Almac, Durham, North Carolina) fully integrated with drug supply management information. Randomization was stratified according to age (Ͻ70 years or Ն70 years) and infarct location (left anterior descending or non-left anterior descending coronary artery).
Study medication (epoetin alfa or matching saline placebo) was administered within 4 hours of successful primary or rescue PCI, defined as time of restoration of TIMI flow grade of 2 or greater in the infarct-related artery. During the initial phase of the REVEAL trial, epoetin alfa and matching placebo were provided free of charge by Centocor Ortho Biotech Clinical Affairs (Bridgewater, New Jersey). However, during the efficacy phase, the company elected to cease providing study medication, and the study sponsor (National Institute on Aging) purchased active study medication from Centocor Ortho Biotech and contracted with Florida Biologix, in Alachua, to manufacture matching placebo. All other treatments, including PCI techniques, were at the discretion of the treating physicians, who were encouraged to adhere to guideline recommendations for the management of patients with STEMI. 19 weeks later. Each CMR examination consisted of (1) a cine CMR for assessment of LV volumes (end-systolic vol-ume and end-diastolic volume), LV mass, and LV function quantified by LVEF and (2) 
Primary and Secondary End Points
The primary efficacy end point of the study was infarct size in the territory of the infarct-related artery, expressed as percentage of LV mass and measured by the first CMR (performed 2-6 days or 48-144 hours) after study medication administra-tion. Secondary end points included infarct size, 3 LV remodeling parameters (LV end-systolic volume, LV end-diastolic volume, and LV mass, each indexed to BSA) and LV function (LVEF) measured by CMR 12±2 weeks after study medication administration (second CMR). The 3 LV remodeling parameters and LVEF measured on the first CMR also were examined. Safety end points included vital signs, hemoglobin level, reticulocyte count, markers of cardiac injury, and clinical events including death, recurrent MI, unplanned PCI, arterial thrombotic events (stent thrombosis), venous thrombotic events (deep venous thrombus, pulmonary embolus), heart fail-ure, and neurological events (stroke, transient ischemic attack).
Statistical Analysis
The primary comparison was infarct size measured by the first CMR between participants who received the highest dose of epoetin alfa deemed safe by the data and safety monitoring board and those who received placebo. The sample size for the 3 patient cohorts in the dose-escalation phase was fixed (n=30 per cohort) as agreed on by the REVEAL study investigators and the US Food and Drug Administration. Because the distribution of infarct size data is consistently nonnormal, the sample size for the efficacy phase was determined with an empirical approach that used available infarct size data from studies carefully matched to the conditions of our investigation (mean [SD] infarct size of 19.5 [10.6] ). The power values were estimated by simulations that suggested a sample size of 55 patients per group in the efficacy phase and 30 patients from the corresponding dose-escalation phase would provide more than 80% power to detect a difference of 20% or greater in infarct size between the 2 treatment groups. The REVEAL trial continued to accrue patients until 110 participants received study medication and competed their first CMR scan in the efficacy phase.
Efficacy data were analyzed on a modified intention-to-treat basis, which excluded 1 patient who was randomized but did not receive study medication. The efficacy cohort comprised all patients from the efficacy phase plus all patients from the 60 000 U cohort of the dose-escalation phase who received study medication and underwent their first CMR.
Baseline differences between the epoetin alfa and placebo groups were evaluated using the Fisher exact test with a mid-P value adjustment for categorical variables and the Wilcoxon rank sum test for continuous variables. Spearman rank correlation coefficients and scatterplots were used to evaluate the relationship between in- Between-group comparisons for all other cardiac variables assessed by CMR were performed with analysis of variance for unadjusted analyses and with analysis of covariance for adjusted analyses. The adjusted analyses controlled for age group, infarct-related artery location, and enrollment phase. Adjustment for enrollment phase was performed to control for implicit differences that may exist between patients recruited in the dose-escalation phase and patients recruited in the efficacy phase. For cardiac variables measured on the second CMR, the adjusted models controlled for values of the same variables obtained on the first CMR. In addition, post hoc comparisons of changes from the first CMR to the second CMR in LV end-systolic volume, LV end-diastolic volume, and LV mass, each indexed to BSA, were performed with analysis of variance. The primary and secondary end points were further analyzed within the prespecified subgroups of patient age (Ͻ70 vs Ն70 years) and infarct-related artery location (left anterior descending vs nonleft anterior descending).
Safety data were analyzed on an astreated basis. The safety cohort comprised all patients who received study medication. Composite safety end points were added to the analysis plan at the suggestion of the data and safety monitoring board and were compared using the Fisher exact test with a mid-P value adjustment. One prespecified interim test of efficacy was performed using the Haybittle-Peto rule. 21 Due to rounding, the interim analysis did not result in a penalty for the final ␣ level. A 2-sided ␣ level of .05 was considered statistically significant. P values were not adjusted for multiple comparisons. All statistical analyses were performed using SAS software version 9.2 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Between October 2006 and November 2009, 223 participants at 22 of 28 US sites were enrolled into the study and randomized; 222 participants received study medication. Of these, 189 had the first CMR performed within 2 to 6 days after study drug administration (24 in the 15 000 U cohort; 27 in the 30 000 U cohort; and 138 in the 60 000 U combined efficacy cohort) ( Figure 1 ). In the entire efficacy cohort, the median time from symptom onset to study drug administration was 6.3 hours (interquartile range, 5.0-7.6 hours) and the median time from study drug administration to first CMR was 66.3 hours (interquartile range, 50.2-118.7 hours). Most participants in this cohort (124/138; 89.9%) underwent follow-up CMR (second CMR) at 12 ± 2 weeks. The last follow-up visit was conducted on February 12, 2010.
The baseline clinical characteristics of the total and efficacy cohorts, stratified by treatment assignment, are summarized in TABLE 1. The active medication (epoetin alfa) group and the placebo group were well matched, al- Abbreviations: PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. a Values are expressed as number (percentage) unless otherwise indicated. b A total of 223 patients were randomized, but only 222 received study medication. c Self-reported information was collected from all patients. Categories were defined by the study and consisted of the following: American Indian/Alaska Native, Asian, black or African American, Native Hawaiian/Pacific Islander, or white. d Includes patients who self-identified as Asian, Native Hawaiian/Pacific Islander, or American Indian/Alaska Native. e Self-reported information was collected from all patients. Categories were defined by the study and consisted of the following: Hispanic/Latino or non-Hispanic/Latino. f Defined as history of high blood pressure as documented by either (1) hypertension diagnosed and treated with medication, diet, and/or exercise or (2) blood pressure level higher than 140 mm Hg (systolic) or 90 mm Hg (diastolic) on at least 2 occasions. g Determined by patient self-report. h Defined as at least 1 of the following: (1) prior total cholesterol level higher than 200 mg/dL (Ͼ5.2 mmol/L), (2) prior lowdensity lipoprotein cholesterol level higher than 100 mg/dL (Ͼ2.7 mmol/L), or (3) treatment with a lipid-lowering agent. i Defined as any history of diabetes, need for antidiabetic agents, or fasting blood glucose level higher than 7 mmol/L (Ͼ126 mg/dL). j For between-group comparison, the P value was less than .05. k Includes both unfractionated and low-molecular-weight heparin. l One patient did not receive the first cardiac magnetic resonance imaging.
though the former had a significantly lower prevalence of diabetes mellitus, less use of rescue PCI, and a longer time from randomization until study drug administration.
Efficacy Analyses
Cardiac variables assessed by CMR in the efficacy cohort are shown in TABLE 2. The number of participants included in each efficacy analysis varied depending on CMR end point availability. The primary study end point of infarct size mea-sured within 2 to 6 days after study medication administration was available for 136 of the 138 patients who underwent CMR and did not differ between the epoetin alfa and placebo groups in either the unadjusted analysis or the adjusted analysis, which controlled for age group, infarct-related artery location, and enrollment phase (Table 2 and FIGURE 2) . There was no association between infarct size and time from study drug administration to first CMR (r = −0.13, P = .14). Infarct size measured at 12±2 weeks after the first CMR did not differ between groups in either the unadjusted or adjusted analyses. Adjusting for baseline clinical characteristics that differed between groups did not affect these findings. As with infarct size, infarct mass did not differ between groups at either time point.
The values for LVEF, LV end-systolic volume indexed to BSA, and LV enddiastolic volume indexed to BSA did not differ between groups in the unadjusted analysis at either time point (Table 2 ). The only end point that differed significantly between groups in the unadjusted analysis was LV mass indexed to BSA ( Table 2) . On the first CMR, the mean LV mass indexed to BSA was 6.7% higher in the epoetin alfa group than in the placebo group (unadjusted P=.04; adjusted P=.03). This difference persisted at 12 weeks but was due to the difference in LV mass indexed to BSA on the first CMR because the change in LV mass indexed to BSA from the first CMR to second CMR did not differ between treatment groups (−6.2 g/m 2 [95% CI, −8.4 to −4.1 g/m 2 ] for epoetin alfa vs −6.5 g/m 2 [95% CI, −8.3 to −4.7 g/m 2 ] for placebo; P=.85).
Subgroup Analyses
Infarct size did not differ between treatment groups according to infarctrelated artery location in either the unadjusted or adjusted analysis within 2 to 6 days (first CMR) or at 12 weeks (second CMR). The interaction between treatment assignment and age group (P = .08) suggests that age group may modify the effect of epoetin alfa on infarct size. Infarct size did not differ between groups among patients younger than 70 years (Figure 2 ). However, among patients aged 70 years or older, the mean infarct size on the first CMR was 41.2% larger in the epoetin alfa group (19.9% LV mass [95% CI, 14.0-25.7% LV mass]) than in the placebo group (11.7% LV mass [95% CI, 7.2-16.1% LV mass]; n = 21; unadjusted P = .03; adjusted P = .02) ( Figure 2) . These results were unchanged when the analyses were further adjusted for presence of diabetes mellitus, which was the only characteristic that significantly differed between the 2 groups (prevalence of 9.1% in the epoetin alfa group and 54.5% in the placebo group). Among patients aged 70 years or older, infarct size on the second CMR remained 40.0% larger in the epoetin alfa group (15.0% LV mass [95% CI, 9.1-20.9% LV mass]) than in the placebo group (9.0% LV mass [95% CI, 4.9-13.0% LV mass]), although this difference was not statistically significant (unadjusted P=.12) . The observed difference was mainly due to the difference in infarct size on the first CMR (adjusted P = .07 when controlling for infarct-related artery location and enrollment phase; adjusted P=.88 when controlling for the previously mentioned items plus the first CMR value of infarct size).
Safety Analyses
Participants who received epoetin alfa had a higher incidence of adverse events (69/125 [55.2%; 95% CI, 46.05%-64.10%]) than those who received placebo (40/97 [41.2%; 95% CI, 31.33%-51.69%]; P = .04) (TABLE 3) . These There were no clinically meaningful differences between treatment groups in hemoglobin levels, reticulocyte counts, or blood pressure at the various time points assessed after administration of study medication (eTable 2 at http://www .jama.com), which likely reflects the fact that only a single infusion of epoetin alfa was administered. Similarly, there were no clinically meaningful differences between treatment groups in the changes in the levels of these variables from baseline or from the preceding time point.
COMMENT
In the REVEAL trial, a single bolus of intravenous epoetin alfa in patients with STEMI who underwent successful primary or rescue PCI failed to demonstrate a reduction in infarct size. There was a significant increase in infarct size in prespecified analyses among older patients. There was also a significant increase in the composite of cardiovascular adverse events that included stent thrombosis. Clinical interest in the use of erythropoietin as a cardioprotective agent emanated from a growing body of experimental evidence showing that erythropoietin's nonerythropoietic effects include anti-inflammatory, antiapoptotic, and angiogenic properties. 10, 22 In preclinical models, erythropoietin promotes neovascularization and induces mobilization of endothelial progenitor cells from bone marrow. 23 In animal models of ischemic myocardial injury, erythropoietin was shown to reduce apoptotic cells, 12, 17 diminish cardiomyocyte loss, 16 improve functional recovery, 14 decrease infarct size, 16, 17 and attenuate infarct expansion. 17
Other Clinical Trials
Previous clinical studies evaluating the effects of erythropoietin on infarct size have yielded conflicting results. In 5 of these studies, infarct size was indirectly estimated from serial measurements of enzymatic markers of cardiac injury. In the HEBE III trial, a single dose of erythropoietin (60 000 U) within 3 hours of primary PCI in patients with STEMI reduced enzymatic infarct size by 6.7% (P=.06) but did not improve LVEF at 6 weeks. 24 In a small pilot study, a single dose of erythropoietin (33 000 U) reduced enzymatic infarct size by 30%. 25 However, in 3 other trials (1 in patients with non-STEMI, 1 in patients with STEMI who were treated with fibrinolysis, and 1 in patients with STEMI who underwent PCI), a single dose of erythropoietin (40 000 U, 40 000 U, and 50 U/kg, respectively) did not reduce enzymatic infarct size. [26] [27] [28] In 2 small studies that assessed infarct size with contrast-enhanced CMR (a powerful, validated tool that allows accurate and reproducible measurement of infarct size 29, 30 ), erythropoietin did not affect infarct size at 4 days 28 or at 6 months. 25 Using CMR, the REVIVAL-3 (Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells) study found that 3 daily doses of erythropoietin (33 000 U each) did not reduce infarct size at 5 days or at 6 months 31 ; 6-month LVEF also remained unimproved.
Taken together with the REVEAL trial, these results indicate that no clinical study to date has shown any beneficial effect of erythropoietin on infarct size measured by CMR. Furthermore, the results in the subgroup of participants aged 70 years or older in the REVEAL trial suggest that erythropoietin may adversely affect infarct size in this high-risk population. Although this concerning finding should be interpreted with caution due to the small number of older patients enrolled in the REVEAL trial and the lack of multiplicity adjustment in the analyses, it suggests the need for added vigilance before enrolling older patients in any future trial evaluating erythropoietin in the setting of MI.
In the small pilot study (N=30) that reported a 30% reduction in enzymatic infarct size with erythropoietin, the erythropoietin treatment group had a greater decrease in LV end-systolic volume than the placebo group, and a similar increase in LV end-diastolic volume. 25 Our larger study failed to replicate these observations. Instead, the epoetin alfa group in the REVEAL trial showed a smaller decrease in LV end-systolic volume indexed to BSA and a larger increase in LV end-diastolic volume indexed to BSA than the placebo group, suggesting a greater reliance on the Frank-Starling mechanism to augment stroke volume. Thus, administration of erythropoietin may be associated with adverse LV remodeling at 3 months.
In the REVEAL trial, we also found a significantly increased risk of death, recurrent MI, stroke, or stent thrombosis with erythropoietin, suggesting an increased thrombotic risk with erythropoietin in patients with STEMI. This is consistent with other studies involving erythropoietin in noncardiac populations. [32] [33] [34] Chronic administration of erythropoietin can lead to increases in vasoconstriction, blood pressure, blood viscosity, 35 and thrombotic risk. 36 Some previous studies in patients with MI did not detect an increased risk of adverse events with erythropoietin, 25, 27, 28, 37, 38 and the HEBE III trial reported a lower risk of major adverse cardiovascular outcomes in patients receiving erythropoietin. 24 On the other hand, REVIVAL-3 observed an increased risk of death, recurrent MI, stroke, or target vessel revascularization in patients who received erythropoietin. 31 Due to these conflicting safety findings, temporary withholding of erythropoietin in patients who are receiving this medication for labeled indications and who sustain an MI merits further study.
Reconciling Animal and Clinical Studies
The promising cytoprotective effects of erythropoietin observed in animal models have not been reproduced in clini-cal studies of acute MI. It is conceivable that the effects of erythropoietin differ among species. For example, although erythropoietin reduced infarct size in a rodent model of coronary occlusion, 17 it failed to do so in a porcine model. 39 Moreover, the average infarct size in the REVEAL trial (approximately 15%-16%) was smaller than infarct sizes reported in animal studies. However, the average infarct size in the REVIVAL-3 study was approximately 27% to 28%, 31 and erythropoietin still was not effective in reducing infarct size. In addition, the doses of erythropoietin used in animal studies (3000-5000 U/kg) were generally higher than those used in the current and other clinical studies. However, the cardioprotective effects of erythropoietin have been demonstrated at doses as low as 150 U/kg in rodents (when administered Յ4 hours of ischemic injury). 40 Importantly, animal studies indicate that there is a therapeutic window of time beyond which the tissueprotective effects of erythropoietin are attenuated; furthermore, the duration of this window is directly related to erythropoietin dose. 40 For example, in a rodent model of coronary ligation, the benefits of erythropoietin at 3000 U/kg can still be observed when administration is delayed up to 12 hours (but not 24 hours) after ischemic injury; whereas at 150 U/kg, these benefits are observed only when erythropoietin is administered within 4 hours (but not 8 hours) of ischemic injury. Furthermore, in a rodent model of ischemia reperfusion, an erythropoietin dose of 3000 U/kg was effective in reducing infarct size if administered at the time of reperfusion (after a 2-hour ischemic injury), but not if infused 4 hours later (M. Talan, unpublished data, September 2010).
In the REVEAL trial, erythropoietin was infused more than 6 hours (on average) after symptom onset. Thus, we cannot exclude the possibility that administration of erythropoietin in our study occurred beyond the putative therapeutic window. The delay in study medication infusion was related in part to the design of the REVEAL trial, which required successful PCI before randomization and was mindful of the importance of door-to-balloon times in patients with STEMI. Although it is possible that earlier administration could have affected the results, erythropoietin did not reduce infarct size in the REVIVAL-3 trial, 31 even though it was administered at the time of PCI.
CONCLUSIONS
In summary, a single bolus of 60 000 U of epoetin alfa in patients with STEMI within 4 hours following successful PCI did not reduce infarct size and was associated with higher rates of adverse cardiovascular events. Subgroup analyses in our study raised concerns about an increase in infarct size among the small number of patients who were aged 70 years or older.
